HLX3901

Phase 1Small molecule

Shanghai Henlius Biotech

HLX3901 is one of 4 small molecule programs targeting SCLC. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SCLCRecruiting

SCLCPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in SCLC

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 2

1 2

Platinum

Bristol-Myers Squibb

Phase 2

1 3

Serplulimab

Shanghai Henlius Biotech

Phase 2

1 4

HLX3901

Shanghai Henlius Biotech

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

SCLC

NCT07416695

Clinical

Trials by Indication[1]

SCLC1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 (DLL3 × DLL3 × CD3 × CD28 Tetra-specific Antibody) in Patients With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT07416695·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HLX3901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HLX3901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HLX3901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Henlius Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Shanghai Henlius Biotech

HLX3901

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

SCLC1 trial

References

Drug Info

Quick Facts

Related News